Mereo BioPharma Group plc (MREO) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
ONE CAVENDISH PLACE LONDON, W1G 0QF |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 69,802 | 57,421 | |||
| Cash and cash equivalent | 69,802 | 57,421 | |||
| Receivables | 464 | 599 | |||
| Prepaid expense | 129 | 1,360 | |||
| Other undisclosed current assets | 4,368 | 4,380 | |||
| Total current assets: | 74,763 | 63,760 | |||
| Noncurrent Assets | |||||
| Operating lease, right-of-use asset | 727 | 1,245 | |||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | 257 | 405 | |||
| Intangible asset, including goodwill, after accumulated amortization | 643 | 1,089 | |||
| Intangible asset, excluding goodwill, after accumulated amortization | 643 | 1,089 | |||
| Total noncurrent assets: | 1,627 | 2,739 | |||
| TOTAL ASSETS: | 76,390 | 66,499 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 6,511 | 7,813 | |||
| Accounts payable | 2,440 | 2,346 | |||
| Accrued liabilities | 4,071 | 5,467 | |||
| Debt | 5,535 | ||||
| Other liabilities | 1,095 | 1,021 | |||
| Other undisclosed current liabilities | 707 | 652 | |||
| Total current liabilities: | 13,848 | 9,486 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 4,394 | ||||
| Long-term debt, excluding current maturities | 4,394 | ||||
| Liabilities, other than long-term debt | 1,573 | 2,082 | |||
| Other liabilities | 565 | 764 | |||
| Operating lease, liability | 187 | 906 | |||
| Derivative instruments and hedges, liabilities | 821 | 412 | |||
| Total noncurrent liabilities: | 1,573 | 6,476 | |||
| Total liabilities: | 15,421 | 15,962 | |||
| Equity | |||||
| Equity, attributable to parent | 60,969 | 50,537 | |||
| Common stock | 3,059 | 2,775 | |||
| Treasury stock, value | (1,230) | ||||
| Additional paid in capital | 539,642 | 486,107 | |||
| Accumulated other comprehensive loss | (18,849) | (17,485) | |||
| Accumulated deficit | (462,883) | (419,630) | |||
| Total equity: | 60,969 | 50,537 | |||
| TOTAL LIABILITIES AND EQUITY: | 76,390 | 66,499 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|
| Revenues | 10,000 | |||
| Net investment income | ||||
| Other income | ||||
| Gross profit: | 10,000 | |||
| Operating expenses | (26,434) | (18,424) | ||
| Other undisclosed operating loss | (20,930) | (19,992) | ||
| Operating loss: | (47,364) | (28,416) | ||
| Nonoperating income | 2,622 | 2,366 | ||
| Investment income, nonoperating | 2,622 | 2,376 | ||
| Interest and debt expense | (2,881) | |||
| Loss from continuing operations before equity method investments, income taxes: | (44,742) | (28,931) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 1,489 | (1,067) | ||
| Loss from continuing operations before income taxes: | (43,253) | (29,998) | ||
| Income tax benefit | 532 | |||
| Net loss available to common stockholders, diluted: | (43,253) | (29,466) | ||
Comprehensive Income ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|
| Net loss: | (43,253) | (29,466) | ||
| Other comprehensive income (loss) | (1,364) | 4,202 | ||
| Comprehensive loss, net of tax, attributable to parent: | (44,617) | (25,264) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.